104983812
liked
$MicroStrategy (MSTR.US)$
I hope Mon do not open high I still want to add more shares most conservative price target 735 most bullish price target 949 by end of Jan
I hope Mon do not open high I still want to add more shares most conservative price target 735 most bullish price target 949 by end of Jan
6
2
$MicroStrategy (MSTR.US)$
idk about y all but I actually want BTC to stay DOWN through the end of the year.
This establishes at a LOWER basis for MSTR adoption of FASB Fair Value Accounting in 2025
After 1/1 the flood gates open
idk about y all but I actually want BTC to stay DOWN through the end of the year.
This establishes at a LOWER basis for MSTR adoption of FASB Fair Value Accounting in 2025
After 1/1 the flood gates open
4
2
$MicroStrategy (MSTR.US)$
BTC start to track back again can start to dca buy the dip
BTC start to track back again can start to dca buy the dip
1
$MicroStrategy (MSTR.US)$
BTC starting reverse up stay focus
BTC starting reverse up stay focus
5
$MicroStrategy (MSTR.US)$
today GG to fill the gap between 270 to 280 to the next Monday may open lower then Xmas period after Xmas we may start to rebound by end of Jan my target price 949
today GG to fill the gap between 270 to 280 to the next Monday may open lower then Xmas period after Xmas we may start to rebound by end of Jan my target price 949
2
3
104983812
liked
$Humacyte (HUMA.US)$
FDA granted full approval for SYMVESS™ (acellular tissue engineered vessel-tyod). This approval authorizes its use in adults as a vascular conduit for extremity arterial injuries requiring urgent revascularization to prevent imminent limb loss, particularly when autologous vein grafts are not feasible.
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
– In clinica...
FDA granted full approval for SYMVESS™ (acellular tissue engineered vessel-tyod). This approval authorizes its use in adults as a vascular conduit for extremity arterial injuries requiring urgent revascularization to prevent imminent limb loss, particularly when autologous vein grafts are not feasible.
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
– In clinica...
11
6
1
104983812
commented on
$Humacyte (HUMA.US)$ Get the pass right away!
Translated
3
3